CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, announces that it has entered into a definitive agreement to divest its Lab Products business to EuroBio Scientific for cash consideration of $170 million. CareDx’s Lab Products business consists of IVD (in vitro diagnostic) PCR kits for rapid deceased donor HLA (human leukocyte antigen) typing, IVD NGS-based (next-generation sequencing) kits for transplant recipient HLA typing globally, and IVD NGS-based monitoring assays for solid organ and stem cell transplant recipients outside of North America.
Read the full article: CareDx Announces Agreement to Divest Lab Products Business to EuroBio Scientific for $170M //
Source: https://www.businesswire.com/news/home/20260415770733/en/CareDx-Announces-Agreement-to-Divest-Lab-Products-Business-to-EuroBio-Scientific-for-%24170-Million-and-Announces-First-Quarter-Preliminary-Financial-Results